Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novo-Pyrexal
- Development stage
- Preclinical
- Lead developer
- Innaxon Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Novo-Pyrexal is a biopharmaceutical Toll-like Receptor 4 (TLR4) agonist developed by Innaxon (also known as Innaxon Biosciences). It is designed to harness the innate immune system for therapeutic benefit in oncology, specifically as a component of immunochemotherapy or as a vaccine adjuvant. By activating TLR4, the drug aims to stimulate immune signaling pathways that enhance the body's anti-tumor response. While some external databases have historically classified it as an antagonist, Innaxon's own pipeline identifies it as an agonist for cancer and vaccine applications. It is currently in preclinical development.
- Brand names
- Novo-Pyrexal
Beyond the preview
Go deeper on Novo-Pyrexal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novo-Pyrexal.